P-Cure
P-Cure develops compact, FDA-cleared gantry-less proton therapy systems for hospital cancer centers. Its synchrotron-based platform fits existing linear accelerator vaults at roughly half the capital cost of traditional systems, serving radiation oncology departments globally.
- Company typePrivate
- Founded2007
- HeadquartersJerusalem, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What P-Cure does
P-Cure Ltd., founded in 2007 by Dr. Michael Marash and headquartered in the Shilat Industrial Zone, Israel, develops a compact gantry-less proton therapy system for cancer treatment. The company's core product is an FDA-cleared and CE-marked proton therapy platform that uses synchrotron-accelerated pencil beam scanning (IMPT) to deliver treatment in both seated and supine patient positions, supported by a six-degree-of-freedom robotic patient positioning system, an integrated 85cm bore diagnostic-quality 4D CT scanner for adaptive therapy, and an orthogonal x-ray imaging system for image-guided verification. The system is designed to fit within existing linear accelerator (linac) vaults, requiring approximately five times less footprint and 50% less shielding than traditional gantry-based proton therapy systems, and is claimed to reduce the capital cost of a proton therapy center by roughly 50% relative to incumbent vendors.
P-Cure operates a direct enterprise sales model targeting hospital radiation oncology departments and proton therapy centers. Revenue is generated through capital equipment sales of the integrated proton therapy system (with estimated per-system pricing of $20-25M for single-room configurations, materially below the $40-50M typical cost of comparable single-room centers and the $140-180M cost of multi-room gantry facilities), supplemented by installation and site-development services including linac-vault conversion, plus ongoing service and support contracts. The company markets a claimed operating breakeven within one year of implementation as a key purchasing driver for hospitals unable to justify traditional proton center investments.
The company maintains a global operating footprint with headquarters in Israel, a US subsidiary (P-Cure Inc.) in Akron, Ohio, and production and translational medicine operations in China. Named installations and clinical collaborations include Northwestern Medicine Chicago Proton Center (USA), Hadassah Medical Center (Israel), Shanghai Proton and Heavy Ion Center (China), Taian Medical Center (China), and Harley Street Proton Center (UK). Distribution is exclusively direct, with no reseller or OEM channels, supported by scientific advisory relationships with radiation oncology leaders from Harvard MGH, the University of Pennsylvania, and Johns Hopkins. The only disclosed funding event is a 2019 $15M round led by Line Medical Group.
P-Cure firmographics
Firmographics- Name
- P-Cure
- Legal name
- P-Cure Ltd.
- Website
- https://p-cure.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- P-Cure develops compact, FDA-cleared gantry-less proton therapy systems for hospital cancer centers. Its synchrotron-based platform fits existing linear accelerator vaults at roughly half the capital cost of traditional systems, serving radiation oncology departments globally.
- Ownership category
- akta.pro rank
P-Cure industry classification
Industry- Product category
- Radiation Therapy Equipment / Proton Therapy Systems
- NAICS
- Irradiation Apparatus Manufacturing (334517), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
- akta.pro primary industry
- Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)
- akta.pro secondary industries
- Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG), Computed Tomography (CT) Systems (HLAHABAB)
Keywords
Where P-Cure is headquartered
LocationHeadquarters
- HQ city
- Jerusalem
- HQ country
- Israel
- HQ region
- Middle East
Offices3 records
Markets served
P-Cure business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Proton Therapy Equipment Sales: P-Cure sells its compact proton therapy system to hospitals and cancer treatment centers. The system includes the synchrotron accelerator, beam delivery system, robotic patient positioning, in-room CT, and control systems. Capital equipment sale model with multi-year revenue recognition.
- Installation and Site Development Services: P-Cure provides installation services for their systems, including vault conversion/construction guidance. The company supports customers through the implementation process including single-floor vault installation which can be completed in approximately one year.
- Service and Support Contracts: Operating breakeven is typically achieved within one year of implementation, suggesting ongoing service and support revenue. The company maintains production, service, and R&D platforms in the US, Israel, and China to support installed base.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Single-room proton therapy system |
| One time/ perpetual license | Multi-year contract | Multi-room expandable center configuration |
| One time/ perpetual license | Multi-year contract | Linac vault conversion |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
P-Cure product offering
Product offeringCore offering
P-Cure designs, manufactures, and sells a compact FDA-cleared gantry-less adaptive proton therapy system for cancer treatment that delivers synchrotron-accelerated pencil beam scanning (IMPT) in both seated and supine patient positions. The integrated solution includes a 4D diagnostic-quality in-room CT, a 6-DOF robotic patient positioning system, and orthogonal X-ray image guidance, and is engineered to fit within existing linear accelerator-style vaults at roughly half the capital cost and one-fifth the footprint of conventional gantry-based proton therapy systems.
Product overview
P-Cure offers a single unified product system — the P-Cure Gantry-Less Adaptive Proton Therapy System — which is an FDA-cleared and CE-marked compact proton therapy solution. The system comprises integrated modules: synchrotron-based pencil beam scanning for beam delivery, an adaptive therapy-driven in-room 4D CT for diagnostic imaging, a robotic patient positioning system supporting both seated and supine positions, and an orthogonal X-ray imaging system for image-guided positioning. These components work together within a compact linac-like vault footprint. The system enables treatment of cancer patients with proton therapy at significantly reduced capital cost (50% reduction) and physical footprint compared to traditional gantry-based proton therapy systems.
Differentiator
Problem solved
Functional benefit
Products and services
- P-Cure Gantry-Less Adaptive Proton Therapy System FDA-cleared and CE-marked compact gantry-less proton therapy system that delivers synchrotron-accelerated pencil beam scanning (IMPT) in both seated and supine patient positions, integrated with a diagnostic-quality in-room 4D CT, a 6-degree-of-freedom robotic patient positioning system, and orthogonal X-ray image guidance. Designed to fit within standard linac-like vaults at roughly half the capital cost and one-fifth the footprint of gantry-based proton therapy systems, and sold to hospital cancer centers, academic medical centers, and specialized proton therapy centers worldwide.
Companies that use P-Cure
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
P-Cure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature6 records
P-Cure partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and strategic.
- Philips Medical SystemscorePhilips Medical Systems is described as a major medical equipment provider with whom P-Cure has forged strategic collaborations. The nature of the collaboration likely involves integration of imaging technologies or co-development of medical device solutions for radiation oncology.
- RaySearchstrategicRaySearch announced expansion of collaboration with P-Cure (October 2023). RaySearch develops treatment planning software for radiation oncology, suggesting technical integration between P-Cure's proton therapy system and RaySearch's treatment planning solutions.
Scale indicators6 records
Recent moves7 records
Expansion highlights4 records
P-Cure competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
P-Cure compliance and trust
Trust signalCompliance3 records
P-Cure financial estimates
Financial estimateRevenue estimate
Valuation estimate
P-Cure leadership team
Management profileNumber of profiles
Profiles8 records
P-Cure funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
P-Cure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about P-Cure
What does P-Cure do?
P-Cure designs, manufactures, and sells a compact FDA-cleared gantry-less adaptive proton therapy system for cancer treatment that delivers synchrotron-accelerated pencil beam scanning (IMPT) in both seated and supine patient positions. The integrated solution includes a 4D diagnostic-quality in-room CT, a 6-DOF robotic patient positioning system, and orthogonal X-ray image guidance, and is engineered to fit within existing linear accelerator-style vaults at roughly half the capital cost and one-fifth the footprint of conventional gantry-based proton therapy systems.
Is P-Cure a public or private company?
P-Cure is a private company. It is classified as venture growth investor backed and is currently operating.
When was P-Cure founded?
P-Cure was founded in 2007. It employs 11 to 50 people.
Where is P-Cure based?
P-Cure is headquartered in Jerusalem, Israel, in the Middle East region.
How does P-Cure make money?
Three revenue lines are on record. Proton Therapy Equipment Sales are the primary driver. The others are installation and Site Development Services and service and Support Contracts.
Does P-Cure have an API?
No public API is recorded for P-Cure.
What industry is P-Cure in?
P-Cure's product category is Radiation Therapy Equipment / Proton Therapy Systems. Its primary akta.pro industry code is HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim), with a secondary code of HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems. Its NAICS code is 334517 and its SIC code is 3841.